What Marathon treats: Main Uses and Benefits

Marathon (Olanzapine) is commonly used across therapeutic domains where additional symptomatic support is needed for conditions marked by heightened patient distress and fluctuating symptoms. Its therapeutic focus includes easing symptoms related to Schizophrenia, controlling acute manic and mixed episodes of Bipolar I Disorder, and, in combination, managing depressive episodes associated with Bipolar Disorder or treatment-resistant depression.

Symptomatic Relief and Stability

Marathon is relevant for easing symptoms related to Schizophrenia, which may involve significant disorganization in thought and perception, and is applied in conditions characterized by periods of increased discomfort to help manage extreme mood and energy fluctuations. It helps address symptom clusters that may become intense, such as hallucinations and delusions, providing support that assists with maintaining a sense of stability. The medicine is considered relevant for easing symptoms in situations involving acute agitation associated with psychotic or manic phases, and may assist with managing these manifestations.

Quick Fact: Relief for Acute Agitation The medicine is applied when appropriate for managing symptoms that interfere with daily comfort and when short-term symptom stabilization is important during severe episodes.

Regulatory References

1. NIH MedlinePlus Drug Information overview

Who Can and Cannot Use Marathon?

Marathon (Olanzapine) eligibility is strictly determined by official regulatory guidelines, defining approved populations and those for whom use is contraindicated or restricted.

Absolute Non-Eligibility

Marathon is contraindicated and must not be used in specific populations as stated in the regulatory labeling:

• Elderly patients with dementia-related psychosis: Use is prohibited due to a significantly increased risk of death and cerebrovascular events (Boxed Warning).
• Patients with a known hypersensitivity to olanzapine or any component of the formulation.
• Patients with untreated narrow-angle glaucoma (as cited in some regulatory documents).
• Patients with Phenylketonuria (PKU): The Orally Disintegrating Tablet (ODT) formulation is prohibited due to the presence of phenylalanine.

---

Age and Physiological Restrictions

Population Group	Eligibility Status (Regulatory Wording)
Pediatric Patients (< 13 years)	Safety and Efficacy Not Established for monotherapy.
Geriatric Patients (ge 65 years)	Restricted/Conditional Use; a lower starting dose should be considered.
Pregnancy	Conditional Use (if potential benefit justifies potential risk to the fetus).
Lactation (Breastfeeding)	Not Recommended; Olanzapine is excreted in human milk.

---

Organ Function and Comorbidity Limitations

Use is restricted and requires caution in patients with hepatic (liver) impairment or renal (kidney) impairment, for whom a lower starting dose (e.g., 5 mg) should be considered. Caution is also advised in patients with conditions predisposing to hypotension or with anticholinergic-sensitive conditions (e.g., prostatic hypertrophy), as mandated by official labeling.

Marathon Interactions with other medicines and products

Official regulatory documents define the interaction profile of Olanzapine primarily through pharmacokinetic (drug concentration) and pharmacodynamic (clinical effect) interactions with other substances.

Interaction Type	Interacting Substance / Category	Official Regulatory Statement
Metabolic (Pharmacokinetic)	Strong CYP1A2 Inhibitors (e.g., Fluvoxamine)	Co-administration leads to a documented increase in Olanzapine plasma exposure (AUC and Cmax), requiring regulatory caution.
Metabolic (Pharmacokinetic)	CYP1A2 Inducers (e.g., Carbamazepine, Smoking)	These substances cause a documented reduction in Olanzapine plasma exposure due to increased metabolism.
Additive Pharmacodynamic	Parenteral Benzodiazepines	Contraindicated Combination with intramuscular (IM) Olanzapine due to the risk of excessive sedation and cardiorespiratory depression.
Additive Pharmacodynamic	Alcohol and CNS-Acting Agents	Co-use potentiates the risk of additive central nervous system (CNS) depression and enhanced orthostatic hypotension.
Additive Pharmacodynamic	Antihypertensive Agents	Documented risk of enhanced antihypertensive effect and orthostatic hypotension.

Interaction-Related Restrictions and Considerations:

• Timing Restriction: The co-administration of IM Olanzapine with parenteral benzodiazepines is officially prohibited.
• Population Note: Regulatory documents note that Hepatic Impairment and non-smoking status may increase the severity of exposure-altering metabolic interactions.
• Food/Herbal: Oral absorption is not significantly affected by food. The herbal product St. John's Wort may reduce Olanzapine plasma concentration.

This structure establishes the necessary context for the product's use as determined by government authorities, without crossing into therapeutic or dosing instructions.

Marathon (deflazacort) is a synthetic glucocorticoid receptor agonist. Following passive diffusion across the plasma membrane, the drug's active metabolite, 21-desacetyldeflazacort, selectively binds to and activates intracellular glucocorticoid receptors (GRs), which are members of the nuclear receptor superfamily.

Upon ligand binding, the activated GR-ligand complex dissociates from chaperone proteins and translocates to the cell nucleus. Within the nucleus, the complex acts as a transcription factor, modifying gene expression through two primary interaction types:

1. Transactivation: The complex binds directly to glucocorticoid response elements (GREs) in the promoter regions of target genes, increasing the transcription of anti-inflammatory proteins such as annexin A1 (lipocortin-1).
2. Transrepression: The complex physically interacts with and inhibits the activity of pro-inflammatory transcription factors, including Nuclear Factor-kappa B (NF-κB) and Activator Protein-1 (AP-1). This interaction is mediated via protein-protein binding, leading to a decreased transcription of numerous pro-inflammatory mediators (e.g., cytokines, chemokines, adhesion molecules).

The resulting downstream cascade involves a broad systemic modulation of the hypothalamic-pituitary-adrenal (HPA) axis via negative feedback, coupled with the systemic suppression of immune cell function and modulation of cellular calcium homeostasis.

Marathon (Olanzapine) is administered through two methods: the oral route and the intramuscular (IM) injection route. The oral dosage forms, which include conventional tablets and orally disintegrating tablets (ODT), are designated for scheduled use, while the short-acting 10 mg powder for injection is reserved for acute, short-term intervention settings.

Oral administration follows a standard once-daily regimen and can be taken without regard to meals. For adults initiating treatment for Schizophrenia, the typical initial dose is 5 mg to 10 mg, with the maximum recommended daily dose established at 20 mg. Dose adjustments for oral therapy are typically separated by intervals of not less than one week to permit stabilization.

For the IM injection used in acute agitation, subsequent 5 mg to 10 mg doses may be administered, but the total IM dose is restricted to 30 mg over a 24-hour period. Procedurally, the ODT must be handled using dry hands or dissolved immediately in an appropriate liquid. A lower starting dose of 5 mg is used for specific populations, such as older adults or patients with known metabolic vulnerabilities, to ensure cautious initiation of the medicine. If an oral dose is missed by several hours, the missed amount is skipped and the following scheduled dose is resumed, without doubling.

Marathon: Recent Clinical Evidence

Evidence for Use in Schizophrenia

Research exploring Marathon utilized short-term randomized controlled trials (RCTs) to assess initial symptom changes and long-term RCTs that monitored participant outcomes over defined time intervals. These studies were conducted during periods of increased symptom activity. Researchers primarily examined how symptoms changed over time using standardized scales, and the research also monitored rates of relapse and hospitalizations as measured outcomes. What remains uncertain is the full characterization of long-term outcomes, particularly those related to the sustained patterns of weight change and metabolic markers. Long-term effects are not fully established.

Evidence for Use in Bipolar I Disorder (Manic and Mixed Episodes)

Marathon was studied for use in conditions characterized by fluctuating or episodic manifestations, specifically during acute manic or mixed episodes of Bipolar I Disorder. Studies reported measurements of how manic symptom scores changed over short periods. Furthermore, the medicine was evaluated in long-term maintenance trials, where research has explored its role in monitoring the time elapsed before the recurrence of any mood episode (manic or depressive). Comparative evidence is lacking against all available treatments for manic episodes, and research on recurrence-focused outcomes for depressive episodes appears less extensive.

Evidence for Use in Bipolar Depression and Treatment-Resistant Depression (As Augmentation)

Marathon was evaluated in research contexts involving fluctuating symptoms when used as an add-on treatment in conditions marked by functional limitations. Research highlights changes measured in depressive symptom scores in adult populations when the medicine was used in combination with an antidepressant. The evidence is limited because the research has focused almost exclusively on using Marathon as an augmentation therapy, not as a standalone treatment for depression.

Long-Term Research and Subgroup Data

The research landscape includes studies designed to observe responses over defined time intervals, with long-term maintenance trials monitoring patients for intervals up to 18 months or longer. Additionally, separate research has examined the medicine’s use in adolescents (aged 13–17). However, results apply only to the populations studied, and long-term effects for certain subgroups are not fully established. Comparative evidence is lacking against all alternative treatments, and evidence quality varies across studies.

Key Studies & References

1. Olanzapine: StatPearls Clinical Overview (NCBI Bookshelf)

Common questions about Marathon (FAQ)

Q: What specific medical condition is Marathon approved to treat?

Official documents indicate the active ingredient in Marathon is approved to treat schizophrenia and bipolar I disorder. This includes treatment for acute manic or mixed episodes and long-term maintenance of the condition. Regulatory labeling contains the complete list of indications.

Q: How does Marathon differ from other established treatments for [condition]?

Marathon is officially classified as an atypical, or second-generation, antipsychotic. Its mechanism of action is described as involving the modulation of multiple receptors in the brain, including those for serotonin and dopamine. This profile distinguishes its mechanism from treatments that may focus only on one type of receptor.

Q: Is Marathon considered a long-term treatment or short-course medication?

Official documentation describes the medicine’s use for both the acute treatment of certain symptoms and the maintenance of improvement over time. Its use in maintenance trials and its scheduled oral regimen suggest it is used for long-term maintenance in certain patient populations.

Q: I've heard people mention [specific mild side effect]. Is this a frequent experience?

Official regulatory documents classify all documented adverse events based on how often they occurred in clinical studies. These categories include very common (occurring in 10% or more of patients) and common (occurring in 1% to 10% of patients). Events not meeting these criteria are typically classified as uncommon or rare.

Q: How long does it typically take for the effects of Marathon to become noticeable?

Regulatory guidance on dose adjustments advises that stabilization is necessary before changes are made. Clinical trials that measured symptom changes generally observed effects over a period of several days to weeks of continuous use.

Q: What is the expected duration of action for one dose of Marathon?

The regulatory documents define the persistence of the active ingredient in the body using its half-life. The reported average terminal half-life of olanzapine is approximately 33 hours in healthy subjects, although the range can vary. The half-life describes the time it takes for the concentration of the medicine in the body to be reduced by half.

Q: Can Marathon be taken with common over-the-counter pain relievers?

Regulatory information advises caution when the medicine is used with any other substance that affects the central nervous system (CNS). This is because combining CNS agents may potentially increase effects like sedation or dizziness. It is important that a healthcare provider is aware of all non-prescription medicines being taken.

Q: Is Marathon suitable for use by older adult populations?

For older adults (ge 65 years) who do not have dementia-related psychosis, official labeling states that a lower starting dose should be considered for this population, and its use requires caution. The medicine is strictly prohibited for use in elderly patients with dementia-related psychosis due to serious risks.

Q: Why are people with pre-existing kidney or liver conditions generally advised against using Marathon?

Regulatory documents advise caution for individuals with hepatic (liver) impairment because the medicine is processed extensively by the liver. A lower starting dose is often considered for these patients due to how the medicine is processed by the body.

Q: Where can I find published studies or research papers about Marathon?

Official, non-commercial information about the medicine can be found on government websites. Authoritative sources like the National Library of Medicine (NIH) and regulatory agency websites often contain details on approved medicines and published research papers.

Q: What does the term 'contraindication' mean in the context of taking Marathon?

A contraindication is a specific condition or circumstance where the official labeling states that the medicine must not be used. This determination is made because the potential risks to the patient are judged to outweigh any potential benefits in that specific situation.

Q: How is Marathon classified in terms of drug schedules or controlled substances?

According to regulatory records, the active ingredient in Marathon is not classified as a controlled substance by major government drug enforcement agencies. This classification means it does not fall under the specific regulations for drugs with high potential for abuse or dependence.

Q: Is there a reason why Marathon is sometimes used alongside other specific medications?

Official labeling confirms that the medicine is approved for use in combination with specific antidepressant treatments. This combination use is specifically indicated for treating depressive episodes associated with bipolar I disorder.

Q: Is it true that the effects of Marathon build up over several weeks?

Official guidance on adjusting the amount of the medicine suggests that changes should be separated by intervals of not less than one week. This is to allow the concentration of the medicine in the body to reach a stabilized level before further adjustments are considered.

Q: What kind of monitoring (like blood tests) is often recommended while using Marathon?

Official regulatory warnings note that the medicine is associated with potential metabolic changes, particularly to blood sugar and lipid levels. Because of this, the labeling recommends that healthcare providers should conduct routine clinical monitoring of these parameters over time.

Q: Is there a generic version of Marathon available?

Yes, the active ingredient in Marathon is available in multiple generic formulations that have been approved by major regulatory bodies. These generic products contain the same active ingredient and meet the same quality and effectiveness standards as the brand-name product.

Q: What should a patient do if they suspect an allergic reaction to Marathon?

Official patient information includes warnings about serious allergic reactions, such as DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms). If any severe or unusual symptoms are suspected, official guidance emphasizes the need for prompt medical attention.

Q: Why did the regulatory body approve Marathon for its indicated use?

Regulatory agencies grant approval after rigorously reviewing clinical trial data. This data must demonstrate that the medicine is effective for the conditions it is intended to treat and that its benefits are judged to outweigh its known risks in the studied populations.

Q: What does the term 'efficacy' refer to when discussing Marathon's clinical data?

Efficacy is the term used in clinical studies to describe a medicine's ability to produce a desired therapeutic effect. The efficacy data for Marathon is based on measurements of symptom changes and other specified outcomes recorded during controlled trials.

Q: Is Marathon prescribed for both men and women?

Yes, the clinical trials used to establish the efficacy and safety of the medicine included both male and female participants. There are no official contraindications or restrictions listed in the regulatory documents based on biological sex.

Q: Can Marathon be crushed, chewed, or split, based on the manufacturer's advice?

The manufacturer provides specific handling instructions for the Orally Disintegrating Tablets (ODTs), which must be dissolved immediately. While not stated directly, conventional tablets are generally designed to be taken whole, and are generally not intended to be altered.

Q: Are there any known interactions between Marathon and common antidepressant medications?

Official documents recommend caution when using Marathon with other medications that affect the central nervous system (CNS). This includes many antidepressants, as combining them may increase the risk of side effects like sedation or dizziness.

Q: What are the signs of a drug interaction that patients should look out for?

Official patient information describes several side effects that may be intensified by an interaction with another drug. These can include increased sedation, dizziness, or symptoms of orthostatic hypotension (low blood pressure when standing).

Q: Does Marathon commonly cause nausea or stomach upset?

The most frequently documented gastrointestinal adverse events, listed as common, are constipation and dry mouth. While other general stomach issues may occur, they were not among the most common events documented in clinical studies.

Q: What is the process for reporting a suspected side effect to the regulatory body?

Regulatory agencies around the world maintain official systems for monitoring the safety of medicines after approval. Patients and healthcare providers are encouraged to report any suspected side effects through these official programs, such as the FDA MedWatch program.

Q: Are there specific patient groups that show better responses to Marathon in studies?

Clinical trials evaluated the medicine's performance separately based on the specific diagnosis and sometimes age group (e.g., adolescents). This data details the observed efficacy in these distinct populations, showing the response observed in each group studied.

Q: Is Marathon considered a potentially habit-forming or addictive medication?

The official labeling addresses the potential for dependence by stating that the medicine has not been systematically studied for its potential for abuse, tolerance, or physical dependence. It is not currently classified as a controlled substance.

Q: What does 'pharmacovigilance' mean in relation to Marathon?

Pharmacovigilance is the ongoing process through which regulatory authorities and manufacturers monitor the safety of a medicine once it is approved and being used by patients. It involves collecting and reviewing data about adverse effects and taking steps to understand and prevent them.

Q: Are there different dosage strengths of Marathon available?

Yes, the medicine is supplied in various dosage strengths for oral tablets and orally disintegrating tablets. These strengths typically range from 2.5 mg up to 20 mg to allow for flexible use.

Q: Why is it important to share a complete list of current medications before starting Marathon?

Official labeling documents that Marathon can have significant interactions with other medicines, particularly those that affect the central nervous system or liver metabolism. Official labeling documents the need to share a complete list of all current medications so that potential risks can be assessed.

Q: What does the patient information leaflet say about what to expect after discontinuing Marathon?

Regulatory documents advise against stopping the medicine suddenly. Abrupt cessation may lead to rare, documented symptoms such as insomnia, nausea, or sweating. Discontinuation or changes in use should always be guided by a healthcare professional.

How to Store and Dispose of Marathon (Olanzapine)

Marathon (Olanzapine) must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F). The medication must be kept in the tightly closed original container and protected from excess heat and moisture; storage in a bathroom is prohibited. The tablets should also be protected from light. All forms of the product must be kept securely out of the sight and reach of children.

For disposal, the drug take-back program or a DEA-authorized collector is the preferred method for unused or expired product. If this is unavailable, the tablets should be mixed with an unappealing substance, sealed in a container, and discarded in the household trash. The product should not be released into the environment or flushed.